Literature DB >> 22640714

Endometrial cancer.

Kimberly K Leslie1, Kristina W Thiel, Michael J Goodheart, Koen De Geest, Yichen Jia, Shujie Yang.   

Abstract

Despite the questions and barriers, the incorporation of molecular therapy into treatment regimens in endometrial cancer is an exciting area of investigation with the potential to improve outcomes. Outside of the development of a reliable screening test for endometrial cancer, converting the disease to a chronic state and improving progression-free survival is our best hope to reverse the concerning trend of decreasing 5-year survival for this disease.

Entities:  

Mesh：

Year:  2012        PMID： 22640714      PMCID： PMC3518445          DOI： 10.1016/j.ogc.2012.04.001

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN： 0889-8545            Impact factor:   2.844


  74 in total

1.  Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial.

Authors:  Meenakshi Singh; Kathleen M Darcy; William E Brady; Rashna Clubwala; Zachary Weber; Jon V Rittenbach; Ali Akalin; Charles W Whitney; Richard Zaino; Nilsa C Ramirez; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2011-08-03       Impact factor: 5.482

2.  PTEN/MMAC1 mutations in endometrial cancers.

Authors:  J I Risinger; A K Hayes; A Berchuck; J C Barrett
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

Review 3.  Endometrial cancer.

Authors:  Andrew J Ryan; Beatrice Susil; Thomas W Jobling; Martin K Oehler
Journal:  Cell Tissue Res       Date:  2005-11-03       Impact factor: 5.249

4.  Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

Authors:  Amit M Oza; Laurie Elit; Ming-Sound Tsao; Suzanne Kamel-Reid; Jim Biagi; Diane Michele Provencher; Walter H Gotlieb; Paul J Hoskins; Prafull Ghatage; Katia S Tonkin; Helen J Mackay; John Mazurka; Joana Sederias; Percy Ivy; Janet E Dancey; Elizabeth A Eisenhauer
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

5.  Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.

Authors:  P J Hoskins; K D Swenerton; J A Pike; F Wong; P Lim; C Acquino-Parsons; N Lee
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

6.  Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor.

Authors:  P G Satyaswaroop; C L Clarke; R J Zaino; R Mortel
Journal:  Cancer Lett       Date:  1992-02-29       Impact factor: 8.679

7.  Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.

Authors:  B Sorbe; H Andersson; K Boman; P Rosenberg; M Kalling
Journal:  Int J Gynecol Cancer       Date:  2007-10-18       Impact factor: 3.437

8.  K-ras activation in premalignant and malignant epithelial lesions of the human uterus.

Authors:  T Enomoto; M Inoue; A O Perantoni; G S Buzard; H Miki; O Tanizawa; J M Rice
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

9.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

Authors:  Pierluigi Benedetti Panici; Stefano Basile; Francesco Maneschi; Andrea Alberto Lissoni; Mauro Signorelli; Giovanni Scambia; Roberto Angioli; Saverio Tateo; Giorgia Mangili; Dionyssios Katsaros; Gaetano Garozzo; Elio Campagnutta; Nicoletta Donadello; Stefano Greggi; Mauro Melpignano; Francesco Raspagliesi; Nicola Ragni; Gennaro Cormio; Roberto Grassi; Massimo Franchi; Diana Giannarelli; Roldano Fossati; Valter Torri; Mariangela Amoroso; Clara Crocè; Costantino Mangioni
Journal:  J Natl Cancer Inst       Date:  2008-11-25       Impact factor: 13.506

10.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.

Authors:  H Kitchener; A M C Swart; Q Qian; C Amos; M K B Parmar
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321
View more
  17 in total

Review 1.  GPER modulators: Opportunity Nox on the heels of a class Akt.

Authors:  Eric R Prossnitz
Journal:  J Steroid Biochem Mol Biol       Date:  2017-03-08       Impact factor: 4.292

2.  Integrated Bioinformatic Analysis of DNA Methylation and Immune Infiltration in Endometrial Cancer.

Authors:  Fangfang Dai; Jinglin Wu; Zhimin Deng; Hengxing Li; Wei Tan; Mengqin Yuan; Dongyong Yang; Shiyi Liu; Yajing Zheng; Min Hu; Chaoyan Yuan; Yanxiang Cheng
Journal:  Biomed Res Int       Date:  2022-06-20       Impact factor: 3.246

3.  Patient-Generated Subjective Global Assessment in relation to site, stage of the illness, reason for hospital admission, and mortality in patients with gynecological tumors.

Authors:  Camila Santos Rodrigues; Gabriela Villaça Chaves
Journal:  Support Care Cancer       Date:  2014-09-16       Impact factor: 3.603

4.  Sugiol suppresses the growth, migration, and invasion of human endometrial cancer cells via induction of apoptosis and autophagy.

Authors:  Hongyan Zhao; Xiaoyue Zhang
Journal:  3 Biotech       Date:  2021-04-23       Impact factor: 2.406

5.  Targeting the glucose-regulated protein-78 abrogates Pten-null driven AKT activation and endometrioid tumorigenesis.

Authors:  Y G Lin; J Shen; E Yoo; R Liu; H-Y Yen; A Mehta; A Rajaei; W Yang; P Mhawech-Fauceglia; F J DeMayo; J Lydon; P Gill; A S Lee
Journal:  Oncogene       Date:  2015-02-16       Impact factor: 9.867

6.  G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth.

Authors:  Whitney K Petrie; Megan K Dennis; Chelin Hu; Donghai Dai; Jeffrey B Arterburn; Harriet O Smith; Helen J Hathaway; Eric R Prossnitz
Journal:  Obstet Gynecol Int       Date:  2013-11-27

7.  A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.

Authors:  Meng Zhou; Zhaoyue Zhang; Hengqiang Zhao; Siqi Bao; Jie Sun
Journal:  BMC Cancer       Date:  2018-01-05       Impact factor: 4.430

Review 8.  Non-Coding RNAs and Endometrial Cancer.

Authors:  Cristina Vallone; Giuliano Rigon; Caterina Gulia; Alberto Baffa; Raffaella Votino; Giulia Morosetti; Simona Zaami; Vito Briganti; Francesco Catania; Marco Gaffi; Roberto Nucciotti; Fabio Massimo Costantini; Roberto Piergentili; Lorenza Putignani; Fabrizio Signore
Journal:  Genes (Basel)       Date:  2018-03-29       Impact factor: 4.096

9.  Integrated Bioinformatic Analysis of a Competing Endogenous RNA Network Reveals a Prognostic Signature in Endometrial Cancer.

Authors:  Leilei Xia; Ye Wang; Qi Meng; Xiaoling Su; Jizi Shen; Jing Wang; Haiwei He; Biwei Wen; Caihong Zhang; Mingjuan Xu
Journal:  Front Oncol       Date:  2019-05-29       Impact factor: 6.244

Review 10.  Long Non-Coding RNAs in Endometrial Carcinoma.

Authors:  Maria A Smolle; Marc D Bullock; Hui Ling; Martin Pichler; Johannes Haybaeck
Journal:  Int J Mol Sci       Date:  2015-11-04       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.